Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron heads west to find new home in Wales

Stem cell specialist ReNeuron Group will start life in new facilities in Wales next month.
ReNeuron heads west to find new home in Wales
The firm is a stem cell specialist...

Stem cell specialist ReNeuron Group (LON:RENE) will start life in new facilities in Wales next month.

From February 29, the firm said its headquarters, research laboratories and manufacturing facilities will be housed in a new purpose-built building on the Pencoed Business Park, just off the M4 in South Wales. Previously the firm was based in Guildford.

Olav Hellebø, chief executive, said: "We are delighted to be moving ReNeuron's existing operations to our new facility at Pencoed, South Wales.

"When fully complete and licensed, we believe the building will house one of the world's most advanced commercial cell therapy manufacturing facilities and we look forward to continuing to work with the Welsh Government to bring this important project to fruition."

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
1506367758_shutterstock_118491940.jpg
September 26 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use